The $19 billion weight loss craze creates new demand for tissue repair, and Conexeu targets gaps in the market
Listed preclinical biotechnology company Conexeu Sciences (stock code: CNXU) recently announced that the preclinical research P.R.O.O.F phase of its CXU platform has been completed, and the company plans to enter the medical beauty injection market based on this. The background of this strategic layout is the explosive growth of the GLP-1 weight loss drug market. The market has reached approximately US$79 billion in 2025 and is expected to double to approximately US$190 billion by 2035. However, this success also came with an unintended consequence: Rapid, significant weight loss can lead to volume loss in patients’ face and body, and existing cosmetic injectable products were not designed with such large-scale repair needs in mind. Miles Harrison, CEO of Conexeu Sciences, said: "GLP-1 is one of the most iconic medical stories of a generation. Its success has created an entirely new type of patient whose bodies are changing faster than the aesthetic industry can cope. Existing injectable products were not designed to fill this gap." To address this market gap, Conexeu plans to enter the market through the FDA's expedited 510(k) route, aiming to submit its first application in the first quarter of 2027. The company is working with It competes with industry giants such as Galderma that have already deployed in this field. Conexeu’s platform technology, CXU, is positioned as a “structural” product designed to provide a temporary scaffold on which the patient’s own cells and signaling molecules can build new tissue, rather than simply filling in volume like traditional fillers.